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TThe Positive and Negative Syndrome Scale (PANSS) in schizophrenia (SZ) is a commonly used tool to evaluate psychiatric symptoms, providing a metric by which treatment effectiveness can be gauged.1 The full scale consists of 30 items assessing symptoms, such 
as Conceptual Disorganization, Hallucinatory 
Behavior, and Blunted Affect, as judged by 
trained raters on a 7-point ordered scale . 
These item ratings are commonly summed to 
yield an overall symptom severity score that in 
turn is used to judge change in symptoms after 
treatment. PANSS item ratings also have been 
used to evaluate changes in clinical status, 
including remission of symptoms. 
The Remission in Schizophrenia Working 
Group previously identified 8 of the 30 
PANSS symptoms for which “remission” could 
be benchmarked.2 The workgroup defined 
remission as a “state in which patients have 
experienced an improvement in core signs and 
symptoms to the extent that any remaining 
symptoms are of such low intensity that 
they no longer interfere significantly with 
behavior and are below the threshold typically 
utilized in justifying an initial diagnosis of 
schizophrenia.” Remission also has been 
described to be a “more stringent standard 
than [treatment] response.2 Specifically, 
the workgroup defined remission in SZ by 
scores of 3 or less (mild) on eight specific 
PANSS items: Delusions, Unusual Thought 
Content, Hallucinatory Behavior, Conceptual 
Disorganization, Mannerisms/Posturing, 
Blunted Affect, Social Withdrawal, and Lack of 
Spontaneity and Flow of Conversation.2 In this 
study, this 8-item subset will be referred to as 
the “Remission set.”
A B S T R A C T
Objective: Total scale scores derived by summing ratings from the 30-item 
PANSS are commonly used in clinical trial research to measure overall symptom 
severity, and percentage reductions in the total scores are sometimes used 
to document the efficacy of treatment. Acknowledging that some patients 
may have substantial changes in PANSS total scores but still be sufficiently 
symptomatic to warrant diagnosis, ratings on a subset of 8 items, referred 
to here as the “Remission set,” are sometimes used to determine if patients’ 
symptoms no longer satisfy diagnostic criteria. An unanswered question 
remains: is the goal of treatment better conceptualized as reduction in 
overall symptom severity, or reduction in symptoms below the threshold for 
diagnosis? We evaluated the psychometric properties of PANSS total scores, 
to assess whether having low symptom severity post-treatment is equivalent 
to attaining Remission.Design: We applied a bifactor item response theory 
(IRT) model to post-treatment PANSS ratings of 3,647 subjects diagnosed 
with schizophrenia assessed at the termination of 11 clinical trials. The 
bifactor model specified one general dimension to reflect overall symptom 
severity, and five domain-specific dimensions. We assessed how PANSS 
item discrimination and information parameters varied across the range of 
overall symptom severity (θ), with a special focus on low levels of symptoms 
(i.e., θ<-1), which we refer to as “Relief” from symptoms. A score of θ=-1 
corresponds to an expected PANSS item score of 1.83, a rating between 
“Absent” and “Minimal” for a PANSS symptom. Results: The application of the 
bifactor IRT model revealed: (1) 88% of total score variation was attributable 
to variation in general symptom severity, and only 8% reflected secondary 
domain factors. This implies that a general factor may provide a good indicator 
of symptom severity, and that interpretation is not overly complicated by 
multidimensionality; (2) Post-treatment, 534 individuals (about 15% of the 
whole sample) scored in the “Relief” range of general symptom severity, but 
more than twice that number (n = 1351) satisfied Remission criteria (37%). 
2 in 3 Remitted patients had scores that were not in a low symptom range 
(corresponding to Absent or Minimal item scores); (3) PANSS items vary 
greatly in their ability to measure the general symptom severity dimension; 
while many items are highly discriminating and relatively “pure” indicators 
of general symptom severity (delusions, conceptual disorganization), others 
are better indicators of specific dimensions (blunted affect, depression). The 
utility of a given PANSS item for assessing a patient depended on the illness 
level of the patient. Conclusion: Satisfying conventional Remission criteria 
was not strongly associated with low levels of symptoms. The items providing 
the most information for patients in the symptom Relief range were Delusions, 
Preoccupation, Suspiciousness Persecution, Unusual Thought Content, 
Conceptual Disorganization, Stereotyped Thinking, Active Social Avoidance, 
and Lack of Judgment and Insight. Lower scores on these items (item scores 
≤2) were strongly associated with having a low latent trait θ or experiencing 
overall symptom relief. The inter-rater agreement between Remission and 
Relief subjects suggested that these criteria identified different subsets of 
patients. Alternative subsets of items may offer better indicators of general 
symptom severity and provide better discrimination (and lower standard 
errors) for scaling individuals and judging symptom relief, where the “best” 
subset of items ultimately depends on the illness range and treatment phase 
being evaluated.
KEYWORDS: Schizophrenia, PANSS, symptom relief, remission, item response 
theory
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Item response theory (IRT) analyses 
of the PANSS have been used to identify 
how different PANSS items measure 
symptom severity within specific symptom 
dimensions.3–6 Most of these studies focused 
on baseline data, and it remains unclear if 
end-point or post-treatment data are similar 
or different in structure. In the first IRT of the 
PANSS, Santor and colleagues4 used non-
parametric IRT to analyze baseline PANSS 
data from 9,205 patients with schizophrenia, 
schizoaffective, or schizophreniform disorder 
who were enrolled in either observational 
studies or clinical trials. Also using non-
parametric models in a follow-up study, Khan 
and colleagues3 analyzed baseline PANSS 
scores from 7,187 patients. Levine et al5 used 
IRT to assess the consistency of the PANSS 
scale using the same dataset as the original 
Marder analysis, with a parametric graded 
response model. Levine did not rank items or 
propose subsets of items for removal. Weak 
PANSS items might be sample dependent 
and could vary across country and stage of 
illness,7,8 with characteristic changes in IRT 
models seen between active and placebo 
interventions.9 Moreover, the methodological 
approach of ranking items within a factor 
domain dismisses the usage of the PANSS 
as a unidimensional measurement when 
item scores are summed across all domains, 
implying that the quality of items using these 
previous analyses are with respect to each 
subdomain and not the entire PANSS scale.
Although PANSS data have been the focus of 
many factor analytic studies in a wide variety 
of samples,10–12 as well as several applications 
of item response theory (IRT) models to 
domain subscales,3–5,9 few if any studies 
have carefully examined the psychometric 
properties of the total score as reflecting 
variation on an overall symptom severity 
dimension, or considered the psychometric 
properties of the items in the remission subset. 
A bifactor IRT model would separately identify 
a general factor that might be independent of 
other specific factors, thus helping separate 
out generalized symptoms from specific 
symptoms. The purpose of the present 
investigation is thus to better understand 
and evaluate the psychometric properties 
of PANSS total scores and the remission set. 
We aimed to determine 1) how well the total 
score and/or the general factor identified in 
an IRT bifactor model work to measure overall 
symptom severity; (2) if there is a subset of 
items that might be superior to using the 
total score to identify patients who achieve 
“relief” from symptoms (i.e., when symptom 
ratings are between “absent” and “minimal” 
in terms of PANSS anchors); and 3) in this 
sample of individuals studied at the end of 
their participation in clinical trials, how the 
remission criteria compare to relief criteria.
To address these questions, we applied a 
bifactor item response theory13–16 model to a 
large sample of ratings on subjects diagnosed 
with schizophrenia assessed at the termination 
of 11 clinical trials. This bifactor model was 
specified to allow for one general dimension, 
representing overall symptom severity, and 
five specific domain dimensions (i.e., positive, 
negative, disorganized, excited, and anxiety/
depression symptoms) representing unique 
variation that cannot be explained by a 
general factor. The utility of subsets of PANSS 
items, including the Remission set, were 
compared to evaluate how symptom relief, or 
mild illness levels, can best be measured. 
A brief review of item response 
theory and bifactor models. The basic 
goal of applying an IRT model is to use a 
mathematical model (typically a logistic 
function) to characterize the relation between 
individual differences on a latent variable (i.e., 
trait levels) and the probability of responding 
in a particular category.17 For example, in 
the well-known graded response model 
(GRM)18 for ordered polytomous items, each 
item is characterized by a set of “parameters” 
that reflect the strength of the relation with 
the latent variable (called “discrimination” 
and symbolized by a) and a set of the 
location parameters (called “thresholds” 
and symbolized by b) that indicate the trait 
levels at which the probability of responding 
above a given category is 0.50. Finally, 
trait levels in IRT are typically reported in a 
z-score like metric such that the mean score 
in the population is zero with a standard 
deviation (SD) of 1. Once estimated, these 
item parameters define the category response 
curves (CRCs) for a given item. To illustrate, 
Figure 1 displays the CRCs for four PANSS items 
that vary in discrimination: a=0.65, 0.99, 
1.58, and 1.92 for Blunted Affect, Difficulty in 
Abstract Thinking, Conceptual Disorganization, 
and Delusions, respectively. For each item, 
from left to right, the CRCs provide a visual 
depiction of the probability of responding in 
Categories 1 to 6 as a function of symptom 
severity . 
Observe that as the item discrimination 
increases, the CRCs become more peaked, and 
are thus more “discriminating” (i.e., responses 
in particular categories convey more precision 
in terms of trait standing). A convenient 
feature of IRT models is that CRCs can be easily 
converted to item information curves (IICs). 
For example, Figure 2 displays the IICs for 
the four items shown in Figure 1. The lowest 
curve corresponds to the least discriminating 
item in Figure 1 and the highest curve 
corresponds to the most discriminating item 
in Figure 1. Simply stated, items with higher 
discriminations provide more information, 
and the location of that information is 
determined by the threshold parameters. 
The IRT concept of information is critically 
important in judging item quality because 
the amount of information, conditional on 
trait level, is inversely related to an item’s 
contribution in reducing an individual’s 
standard error of measurement. Standard 
errors of measurement are one divided by 
the square root of the information. As we 
will show shortly, item information functions 
can be added together to form an overall test 
information curve (TIC) used to judge the 
overall quality and measurement precision a 
set of items provides.
Most applications of IRT modeling are 
application of so-called “unidimensional” 
models where there is a single latent variable 
of interest. With the PANSS, however, we know 
from previous research and our own data 
explorations that item responses are highly 
multidimensional. This multidimensionality 
can severely bias parameter estimates when 
fitting a unidimensional (one trait) IRT model. 
However, fitting IRT models within separate 
factor domains omits the usage of the total 
PASS score as a measure of illness level and 
evaluates items only with respect to others in 
that particular domain. For this reason, in the 
present study, we fit a bifactor IRT model.15 
The bifactor model specifies that each item 
is an indicator of a general trait (symptom 
severity here), as well as one secondary 
specific dimension (e.g., positive symptoms). 
The general factor and the specific dimensions 
are orthogonal. As described below, although 
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the bifactor is a multidimensional model, we 
can ultimately “collapse” the model down into 
a single dimension in order to study how well 
PANSS items are reflecting the general trait 
of symptom severity, while simultaneously 
controlling for the biasing effects of secondary 
or nuisance dimensions. Although the specific 
dimensions are controlled for in the bifactor 
model, we can derive CRCs and IICs in a 
bifactor model that are analogous to their 
unidimensional IRT model counterparts. 
METHODS
Data and demographics. A total of 
3,647 subjects with SZ from 11 different trials 
were included in this study and are detailed 
further in Table 1. The Item Category 7 was 
infrequently endorsed, so was recoded to Item 
Category 6. A total of five different medications 
(paliperidone ER [extended release], 
paliperidone palmitate, olanzapine, quetiapine, 
and risperidone) were compared with a placebo 
intervention. All subjects were off antipsychotic 
medications at the baseline assessment. All 
subjects provided written informed consent 
after receiving a complete description of the 
study, which was conducted in accordance with 
the latest version of the Declaration of Helsinki. 
The length of time varied from 1 day to 5 days 
depending on the study so not all subjects were 
strictly medication-free because of washout 
variability. Benzodiazepines were allowed to 
certain limits to control agitation. All except 
one SZ trial used PANSS scores of 60 to 120 or 
70 to 120 for inclusion criteria. Further details 
are published in the original articles (Table 
1).19–29 
Fitting the bifactor IRT model. 
Factor analysis. Our ultimate goal is to fit a 
bifactor IRT model with one general factor 
(representing global symptom severity) and 
five specific domain factors (positive, negative, 
disorganized, excited, and anxiety/depression 
symptoms). Prior to fitting the IRT model, 
we first conducted a set of exploratory and 
confirmatory factor analyses to 1) judge the 
viability of a bifactor structure for the PANSS 
data, 2) determine the degree to which 
each item loads on the general factor and 
each of five specific domain factors, and 3) 
identify items with sizeable cross-loadings on 
multiple factors. Such items are known to bias 
bifactor solutions depending on the degree 
of violation.30 Specifically, we conducted an 
exploratory bifactor factor analysis using the 
Schmid-Leiman technique available in the 
psych library31 in R 3.41 (R Core Team, 2017) 
using minres estimation and oblimin rotation 
of polychoric correlations. We then fit both 
unidimensional and bifactor confirmatory 
factor models using diagonally weighted 
least square (DWLS) estimation available in 
the lavaan package32 in R. Our goal of these 
preliminary analyses was to judge the fit of 
a bifactor structure using standard indices 
(CFI, RMSEA, and SRMR) and to test the 
superiority of a bifactor model relative to a 
unidimensional, single trait, model. 
FIGURE 2. Item information curves for 4 Positive and Negative Syndrome Scale (PANSS) items that vary in 
discrimination
FIGURE 1. Category response curves for 4 Positive and Negative Syndrome Scale (PANSS) items that vary in 
discrimination—Blunted Affect and Difficulty in Abstract Thinking would be considered weak items, while Conceptual 
Disorganization and Delusions are strong items with scores that provide much information about the latent trait.
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TABLE 1: Demographic information of study population
INTERNAL ID NCT TREATMENTS N TX 
N 
PLACEBO N 
MALE 
(%) 
PANSS 
(MEAN) 
PANSS
(SD) 
AGE IN YEARS 
(MEAN) 
AGE IN 
YEARS 
(SD)
INCLUSION
R092670-SCH-201 NCT00074477 paliperidone palmitate 126 52 178 65.7% 81.10 13 38.98 10.47
Subjects diagnosed with schizophrenia according to 
DSM-IV (disorganized type [295.10], catatonic type 
[295.20], paranoid type [295.30], residual type [295.60], 
or undifferentiated type [295.90]) at least 1 year before 
screening; total PANSS score must be between 70 and 
120, inclusive, at screening, and 60 and 120, inclusive, at 
Day 1 (before start of double-blind study drug)
R076477-SCH-304 NCT00077714 
paliperidone extended-
release 
242 73 315 73.0% 93.60 10.7 41.81 10.56
Diagnosis of schizophrenia according to DSM-IV criteria 
(295.10, 295.20, 295.30, 295.60, 295.90) at least 1 year 
before screening; experiencing an acute episode, with a 
PANSS total score at screening between 70 and 120
R076477-SCH-305 NCT00083668 
paliperidone extended-
release, olanzapine 
516 0 516 66.5% 93.90 11.8 36.74 10.54 
Experiencing an acute episode, with a total PANSS score at 
screening between 70 and 120
R076477-SCH-302 NCT00085748 
paliperidone  
extended-release 
63 30 93 25.8% 105.20 13.9 69.58 4.56
DSM-IV diagnosis of schizophrenia (295.10, 295.20, 
295.30, 295.60, 295.90) at least 1 year before screening; 
total PANSS score at screening and baseline (Visit 2) 
between 70 and 120, inclusive
R076477-SCH-301 NCT00086320 
paliperidone  
extended-release 
63 30 164 61.0% 92.10 11.3 39.78 9.8
DSM-IV diagnosis of schizophrenia (295.10, 295.20, 
295.30, 295.60, 295.90); Diagnosis of schizophrenia 
at least 1 year before screening; experiencing an acute 
schizophrenic episode with a total PANSS score between 
70 and 120, inclusive, both at screening and at baseline 
(the start of the run-in phase)
R092670-PSY-3004 NCT00101634 paliperidone palmitate 283 89 372 63.2% 87.00 11 40.01 11.28
Patients who meet diagnostic criteria for schizophrenia 
according to DSM-IV for at least 1 year who meet PANSS 
score criteria and have BMI of >15.0kg/m2; PANSS total 
score at screening and baseline of 70 to 120, inclusive
R092670-PSY-3003 NCT00210548 paliperidone palmitate 139 98 237 67.1% 91.00 11.9 39.07 10.36
Met diagnostic criteria for schizophrenia according to DSM 
IV (disorganized type [295.10], catatonic type [295.20], 
paranoid type [295.30], residual type [295.60] or 
undifferentiated type [295.90]) for at least 1 year before 
screening; a total PANSS score at screening and at baseline 
of between 70 and 120, inclusive
R092670-PSY-3002 NCT00210717 
paliperidone palmitate, 
risperidone 
576 0 576 58.5% 90.80 12.1 40.7 11.69
Met diagnostic criteria for schizophrenia according to 
DSM-IV (disorganized type [295.10], catatonic type 
[295.20], paranoid type [295.30], residual type [295.60], 
or undiffe entiated type [295.90]) for at least 1 year 
before screening; a total PANSS score between 60 and 
120, inclusive
R076477-SCH-3015 NCT00334126 
paliperidone extended-
release, quetiapine 
170 34 204 58.3% 92.80 12.4 35.92 10.76
Met DSM-IV diagnosis of schizophrenia (paranoid, 
disorganized or undifferentiated type); score of ≥4 on at 
least two of a subset of selected PANSS items and a total 
score on these five items of ≥17; score of ≥5 on the CGI-S
R092670-PSY-3007 NCT00590577 paliperidone palmitate 333 104 437 65.9% 87.30 11.7 39.42 10.7
Met diagnostic criteria for schizophrenia according to 
DSM-IV (disorganized type [295.10], catatonic type 
[295.20], paranoid type [295.30], residual type [295.60] 
or undifferentiated type [295.90]) for at least 1 year 
before screening; prior medical records, written docu-
mentation, or verbal information obtained from previous 
psychiatric providers obtained by the investigator must 
be consistent with the diagnosis of schizophrenia; a total 
PANSS score at screening of between 70 and 120, inclusive 
and at baseline of between 60 and 120, inclusive.
R076477-SCH-303 NCT00650793 
paliperidone extended-
release, olanzapine 
446 109 555 50.6% 92.90 9.2 37.15 10.86
Subjects must have been diagnosed with schizophrenia 
according to DSM-IV (295.10, 295.20, 295.30, 295.60, 
295.90) at least 1 year prior to screening; subjects must be 
experiencing an acute episode, with a total PANSS score at 
screening between 70 and 120
NCT: clinicaltrials.gov number; TX: treatment; N: number; SD: standard deviation; DSM-IV: Diagnostic and Statistcal Manual of Mental Disorders, Fourth Edition; PANSS: Positive and Negative Syndrome Scale; BMI: body mass index; CGI-S: 
Clinical Global Impression-severity
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Finally, we also used the confirmatory 
bifactor solution to compute two important 
indices. The first is the explained common 
variance per item (ECVI), which is simply an 
item’s squared loading on the general factor 
squared divided by the communality. ECVI 
values from 0.50 to 1.0 indicate that the 
item is a more “pure” univocal measure of the 
general factor (symptom severity here), and 
ECVI values less than 0.50 indicate that the 
item is a relatively better measure of a specific 
dimension. We also computed two model-
based reliability coefficients, omega ω and 
omega hierarchical ωH.
33 ω values indicate 
the degree to which observed scores reflect all 
reliable sources of common variance (i.e., the 
general factor and the five specific factors). 
ωH reflects the degree to which variance in 
total scores reflects the general symptom 
severity factor. As ωH values approach 1, 
total scores are unambiguous indicators of 
relative standing on the common dimension, 
uncontaminated by specific dimensions. The 
difference in ω and ωH indicate the degree to 
which reliable variance is contaminated by the 
multidimensionality of the items. 
Estimating IRT bifactor model parameters.  
A bifactor IRT model was estimated using 
the mirt34 library in R. The model specified 
one general factor and five specific domain 
factors, where each item was allowed to 
load on the general and only a single specific 
factor. For each item, the model estimated 
five discrimination parameters per item 
(one for the general, and five for the specific 
dimensions), and four intercept parameters 
(one for each between category boundary). 
These estimated parameters are called 
“conditional” parameters and reflect the 
relation between the item and each latent 
trait conditional on the other traits being zero 
(i.e., at the mean of the other dimensions). 
As such they are difficult to meaningfully 
interpret.14 We thus transformed the 
conditional IRT parameters into so-called 
“marginal” parameters using the formula 
provided by Toland et al.35 These marginal IRT 
parameters better reflect the relation between 
trait standing and the item responses. Finally, 
the marginal IRT parameters were used 
to construct a pseudo-IRT unidimensional 
model that included only the general factor 
(symptom severity) and excluded the specific 
factors using methods described by Toland et 
al.35 In this final model, each item has a single 
discrimination parameter and five thresholds. 
In turn, this final model was used to derive 
CRCs and IICs for each item, as well as other 
derived indices. 
To judge the psychometric qualities of the 
remission set, two analyses were performed. 
First, we computed the remission status for 
each subject using the criterion defined for 
the Remission set (i.e., item scores ≤3). We 
then used the final IRT model to estimate each 
individual’s standing on the latent trait using 
expected a posteriori scoring (EAP).36 We then 
compared the distribution of symptom severity 
scores for the judged remitted versus non-
remitted groups. Second, we computed TICs 
based on just the eight Remission set items to 
discern how discriminating this item set is with 
respect to symptom severity and where along 
the latent trait the Remission set provides 
the best discrimination. For comparative 
purposes, we derived TICs for three alternative 
eight-item sets and compared them to the 
Remission set. Specifically, we formed TICs 
based on eight items that A) had the highest 
IRT discrimination parameter (i.e., the most 
discriminating items), B) had the highest 
ECVI (i.e., the most univocal items), and C) 
provided the most information in the low trait/ 
symptom relief range, where low was judged 
as trait standing of θ=( -1,-4). 
This trait level value was selected based 
on the item rating anchors of the PANSS 
(1=absent, 2=minimal, 3=mild, 4=moderate, 
5=moderate/severe, 6=severe, 7=extreme). 
The theta value was selected based on 
inspection of an expected average item 
response that was based on linking the item 
score metric to the latent trait metric using 
a test response curve, which is basically the 
weighted sum of CRCs divided by 30 (items). 
This curve is shown in Figure 3. We used this 
curve to discern the value of the latent variable 
that predicts an item score of 2 (minimal) or 
less. At trait level= -1, the expected item score 
across all 30 items is 1.83, which lies between 
the score anchors of either “Absent=1” or 
“Minimal=2” on the PANSS scale. 
FIGURE 3. Expected item score as a function of symptom severity level—Setting item thresholds ≤2 typically map to 
the trait level below a group-mean.
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RESULTS
Standardized factor loading results for the 
exploratory and confirmatory bifactor models 
are shown in Table 2. Items belonging to the 
eight-item Remission set are bolded and 
italicized. In the exploratory Schmid-Leiman 
analysis, all items loaded significantly on 
the general factor and loaded highest on the 
hypothesized specific factor. However, 10 
items have sizable (>0.20) cross-loadings 
on multiple group factors. This violates the 
assumed independent cluster structure of the 
confirmatory bifactor model (i.e., each item 
loads on one and only one specific factor) and 
thus will be a source of misfit and possible 
parameter bias in the confirmatory bifactor 
model and subsequent bifactor IRT model. 
The confirmatory bifactor model in the 
right panel had a chi-square (c2) of 12,833 
(df=375), CFI =0 .97, RMSEA =0.095, and 
SRMR=0.072. Although the parameter 
estimates are reasonable and CFI is well above 
the traditional benchmark of 0.90 (or 0.95), 
these values indicate only a marginal fit at 
best. Part of the lack of fit can be attributed 
to cross-loadings that are forced to be zero 
in the confirmatory model. Other sources of 
TABLE 2. Standardized factor loadings from Schmid-Leiman exploratory bifactor analysis and confirmatory bifactor analysis
SYMPTOM 
SCHMID-LEIMAN EXPLORATORY CONFIRMATORY SOLUTION
ECVI
G F1 F2 F3 F4 F5 G F1 F2 F3 F4 F5
Blunted Affect 0.34 0.66 -- -- -- -- 0.45 0.64 -- -- -- -- 0.33
Emotional Withdrawal 0.49 0.73 -- -- -- -- 0.58 0.68 -- -- -- -- 0.42
Poor Rapport 0.50 0.59 -- -- -- 0.23 0.61 0.50 -- -- -- -- 0.60
Passive Apathetic Social Withdrawal 0.47 0.70 -- -- -- -- 0.57 0.64 -- -- -- -- 0.44
Lack of Spontaneity Conversation 0.37 0.61 -- -- -- -- 0.47 0.57 -- -- -- -- 0.40
Motor Retardation 0.30 0.49 -- 0.22 -- -- 0.38 0.44 -- -- -- -- 0.43
Active Social Avoidance 0.53 0.48 -- -- -- -- 0.62 0.37 -- -- -- -- 0.74
Delusions 0.72 -- -- -- 0.59 -- 0.71 -- -- -- 0.30 -- 0.85*
Hallucinatory Behavior 0.61 -- -- -- 0.42 -- 0.61 -- -- -- 0.35 -- 0.75
Grandiosity 0.50 -- -- -- 0.32 0.21 0.48 -- -- -- 0.38 -- 0.61
Suspiciousness/Persecution 0.68 -- -- -- 0.40 -- 0.70 -- -- -- 0.38 -- 0.77*
Stereotyped Thinking 0.56 -- 0.44 -- -- -- 0.68 -- 0.32 -- -- -- 0.82*
Somatic Concern 0.37 -- -- 0.43 -- -- 0.38 -- -- 0.40 -- -- 0.47
Unusual Thought Content 0.66 -- -- -- 0.51 -- 0.67 -- -- -- 0.33 -- 0.80*
Lack of Judgment and Insight 0.54 -- 0.34 -- -- -- 0.63 -- 0.1 -- -- -- 0.98*
Conceptual Disorganization 0.62 -- 0.48 -- 0.21 -- 0.73 -- 0.23 -- -- -- 0.91
Difficulty in Abstract Thinking 0.46 0.21 0.33 -- -- -- 0.55 -- 0.42 -- -- -- 0.63
Mannerisms and Posturing 0.40 -- 0.40 -- -- -- 0.50 -- 0.67 -- -- -- 0.36
Poor Attention 0.54 -- 0.51 -- -- -- 0.65 -- 0.55 -- -- -- 0.58
Disturbance of Volition 0.45 0.27 0.42 -- -- -- 0.59 -- 0.46 -- -- -- 0.62
Preoccupation 0.60 -- 0.33 -- 0.22 -- 0.74 -- 0.57 -- -- -- 0.63
Disorientation 0.45 -- 0.20 -- -- -- 0.52 -- 0.66 -- -- -- 0.38
Excitement 0.66 -- 0.21 0.20 -- 0.38 0.70 -- -- -- -- 0.44 0.72
Hostility 0.66 -- -- -- -- 0.59 0.66 -- -- -- -- 0.35 0.78*
Uncooperative 0.63 0.20 -- -- -- 0.50 0.70 -- -- -- -- 0.40 0.75
Poor Impulse Control 0.61 -- -- -- -- 0.46 0.62 -- -- -- -- 0.46 0.64
Anxiety 0.55 -- -- 0.64 -- -- 0.58 -- -- 0.40 -- -- 0.68
Guilt Feelings 0.37 -- -- 0.51 -- -- 0.35 -- -- 0.56 -- -- 0.28
Tension 0.61 -- 0.21 0.52 -- -- 0.69 -- -- 0.35 -- -- 0.80*
Depression 0.41 -- -- 0.61 -- -- 0.42 -- -- 0.55 -- -- 0.37
Note: Items in the Remission set are bolded and italicized. In the exploratory model, all loadings <0.20 are suppressed. G=global symptom severity, F1 = negative, F2=disorganized, 
F3=anxiety/depression, F4=positive, and F5=excited; * indicates the top 8 items in terms of ECVI
ECVI: explained common variance per item
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misfit include small unmodeled correlated 
residuals. Finally, the fit of a unidimensional 
model yielded a c2 of 37,872 (df=405), 
CFI=0.917, RMSEA=0.159, and SRMR=0.123, 
all indicating that the unidimensional model 
significantly worsens the fit relative to the 
bifactor. That is, there is statistically significant 
multidimensionality in the PANSS ratings 
that needs to be accounted for by the bifactor 
model. 
The last column in Table 2 displays the ECVI 
index values with an asterisk (*) next to the 10 
items with the largest ECVI. Inspection of these 
values along with the loadings on the general 
and specific factors indicate a great diversity 
in the PANSS items in terms of measurement 
properties. Specifically, while many items 
are highly discriminating (i.e., high factor 
loadings) and relatively “pure” indicators of 
general symptom severity (Delusions, Lack of 
Judgment, Conceptual Disorganization), others 
are better indicators of specific dimensions 
(Blunted Affect, Mannerisms and Posturing, 
and Depression). Moreover, the relatively 
small loadings (<0.50) on specific domain 
Factors F4 (positive) and F5 (excited) indicate 
these factors are not well determined. Finally, 
ω reliability was 0.96 and ωH was 0.88 
indicating that 88 percent of (unit-weighted) 
total score variation can be attributed to 
variation in general symptom severity, and 
only eight percent reflected secondary domain 
factors. This implies that the total scores are 
an excellent indicator of symptom severity and 
interpretation is not overly compromised by 
multidimensionality. 
 PANSS IRT bifactor model. For efficiency, 
conditional and marginal IRT parameter 
estimates are not shown. Instead, Table 3 
displays the final “pseudo-unidimensional” IRT 
model parameters derived from the marginal 
IRT bifactor model. The column labeled a 
contains the discrimination parameters 
reflecting how well each PANSS item functions 
as an indicator of global symptom severity. 
The columns labeled b contain the threshold 
parameters indicating the trait level necessary 
to respond above a given category. We note 
that some of these values are extremely high, 
suggesting problems in category labeling that 
are beyond the scope of discussion here. 
To further evaluate the remission set, Figure 
4 displays the TIC for the entire 30 items 
and for the four 8-item subsets, R, D, I, and 
U. Figure 4 also displays the corresponding 
conditional standard errors of measurement. 
It is clear from these figures that the 30 
items provide much better measurement 
precision relative to any eight-item subset. 
More importantly, however, it appears that 
the remission subset is the least informative 
and thus the least precise subset in terms 
of scaling individuals on a global symptom 
severity dimension. Generally speaking, the 
best subset to judge symptom relief in terms 
of information and conditional standard error 
is the set of the most discriminating items. 
The set based on the information criterion, by 
design, performs slightly better in the lower 
symptom severity/ symptom relief ranges  
(θ≤ -1).
Also, shown in Table 3 are four 8-item 
subsets. These were derived as follows. The 
R subset contains the eight items used to 
judge remission as suggested by Andreasen 
et al.2 The U subset are eight items with the 
highest ECVI in Table 2. These items are the 
most univocal or pure indicators of symptom 
severity. The D subset are the eight items with 
largest discrimination parameters. Finally, the 
TABLE 3. Item discrimination and threshold parameters from the pseudo-unidimensional IRT model
SYMPTOM a b1 b2 b3 b4 b5 R U D I
Blunted Affect 0.65 -3.63 -1.41 1.47 4.29 7.13 X
Emotional Withdrawal 1.05 -2.51 -1.01 0.91 2.86 4.42
Poor Rapport 1.09 -1.45 -0.01 1.77 3.29 4.65
Passive Apathetic Social Withdrawal 1.03 -2.4 -0.92 0.99 2.56 4.12 X
Lack of Spontaneity Conversation 0.77 -2.04 -0.22 1.97 3.88 5.73 X
Motor Retardation 0.57 -0.69 1.67 4.76 7.7 10.43
Active Social Avoidance 1.35 -1.71 -0.46 1.15 2.47 3.75 X
Delusions 1.92 -1.3 -0.36 0.55 1.46 2.3 X X X X
Hallucinatory Behavior 1.51 -0.63 0.15 0.89 1.64 2.77 X
Grandiosity 1.08 0.05 1.12 2.19 3.43 4.87
Suspiciousness/Persecution 2 -1.11 -0.24 0.71 1.63 2.59 X X X
Stereotyped Thinking 1.4 -1.61 -0.39 1.11 2.5 4.1 X X
Somatic Concern 0.77 -0.8 1.08 2.9 4.5 6.44
Unusual Thought Content 1.75 -1.28 -0.34 0.9 1.93 2.82 X X X X
Lack of Judgment and Insight 1.17 -2.23 -0.85 0.65 2.21 3.35 X X
Conceptual Disorganization 1.58 -1.45 -0.32 0.89 1.95 3.07 X X X X
Difficulty in Abstract Thinking 0.99 -2.78 -1.32 0.51 2.14 3.91
Mannerisms and Posturing 0.82 -0.81 0.59 2.9 4.96 6.98 X
Poor Attention 1.27 -1.26 0.04 1.71 3.08 4.51
Disturbance of Volition 0.96 -1.66 -0.24 1.79 3.91 5.76
Preoccupation 1.75 -1.35 -0.27 0.98 2.1 3.28 X X
Disorientation 0.93 0.22 1.52 3.69 5.39 7.21
Excitement 1.95 -0.44 0.41 1.42 2.42 3.24 X
Hostility 1.71 0.04 0.96 1.97 2.85 3.63 X X
Uncooperative 1.57 -0.02 1.01 1.94 2.91 4.04
Poor Impulse Control 1.57 -0.32 0.71 1.96 3.07 4.18
Anxiety 1.42 -1.05 0.13 1.43 2.42 3.68
Guilt Feelings 0.74 0.35 1.94 3.77 5.6 7.54
Tension 1.83 -0.93 0.15 1.39 2.44 3.52 X X
Depression 0.85 -0.52 0.91 2.54 4.18 5.88
NOTE. Items in the Remission set are bolded and italicized. 
 
a=item discrimination; b=item threshold; R=remission set; U=most unidimensional as judged by ECVI (explained 
common variance per item); D=most discriminating as judged by discrimination; I=most informative at low 
symptomology levels
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I subset are the eight items that provide the 
most information at trait levels less than -1. 
In evaluating the remission set, 37 percent 
of all subjects met the criteria for “Remission.” 
Only 1 in 3 “Remitted” patients were in the 
Symptom Relief range (θ≤ -1); a “Remitted” 
patient was twice as likely to have mild or 
greater symptoms than to have absent/
minimal symptoms, as shown in Figure 3. 
The average symptom severity of a remitted 
patient was  
θ= -0.80 (SD=0.77) and the average severity 
of the non-remitted patients was θ=0.47 
(SD=0.86). This difference was statistically 
significant, but with large overlap between the 
two groups (Figure 5). The overlap coefficient37 
between the Remitted and Non-Remitted 
Coefficients was 0.435, as shown in Figure 6. 
The PANSS symptom thresholds that 
correspond to “Relief” depend on the 
sensitivity one wishes to establish. A stricter 
threshold (all 8 symptoms ≤2) marks only 
eight percent of subjects, and 80 percent 
of subjects within the Relief range for the 
latent trait θ as shown in Table 5 and Figure 6. 
The overlap coefficient for this threshold for 
FIGURE 4. The item information was used to evaluate how different item subsets assessed patients over the entire illness range. Secondarily, we assessed which symptoms best identified 
those subjects within the Relief range, defined to be a latent trait level in the (-4, -1) range on the general Positive and Negative Syndrome Scale (PANSS) dimension. This subset was 
equivalent to those items with the largest Slope/Discrimination values, and was superior to using either the items with the largest ECVI (explained common variance per item) or those 
items used for Remission. However, retaining all PANSS items was superior to using subsets over all ranges, suggesting that restricting evaluations to subsets of items omits core features 
associated with the latent trait.
FIGURE 5. Distribution of expected a posteriori scoring (EAP) symptom severity scores for remitted and non-remitted 
groups—When measured along the general dimension, the remitted and non-remitted groups showed considerable 
overlap, with a statistically significant difference in the mean θ scores (p<0.001.) Roughly 37% of all subjects met 
remission criteria post-treatment, but 2 out of 3 remitted patients had scores that were not in a low symptom range  
(θ≤ -1).
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Relieved and non-Relieved subjects was 27 
percent. When instead setting the threshold 
for Relief symptoms at 3 or less, similar to the 
Remission criteria, roughly 37 percent of all 
subjects were considered to satisfy criteria for 
Relief. The overlap coefficient was 32 percent. 
However, only one in three of these subjects 
was in the Relief range for the latent trait θ. 
Although there were similar percentages of 
subjects flagged with the Remission criteria, 
the subjects identified by Relief and Remission 
were different. The Cohen’s kappa for the Relief 
criteria and Remission criteria when using the 
same threshold was 0.69, as shown in Table 4. 
When using different thresholds (Relief ≤2), 
the Cohen’s kappa value was 0.23. Collectively, 
this suggests that these item subsets differ 
substantially in the type of patients they 
identify. The Relief item subset can be set 
more liberally to include more patients, but 
the patients that the Relief criteria did identify 
were, on average, still less ill in general 
severity than were the individuals identified 
using Remission criteria, with greater 
separation between those who did and did not 
meet the criteria.
DISCUSSION
The overarching objectives of this research 
were to use a bifactor model, both factor 
FIGURE 6. The distributions of the remitted and non-remitted patients showed a large overlap (43.5%) in general severity. The Relief criteria had less overlap between patients who did 
and did not qualify, for all thresholds assessed.
TABLE 4. Relief and remission criteria
THRESHOLD 
KAPPA (RELIEF 
CRITERIA, 
REMISSION 
CRITERIA)
% OF SUBJECTS 
MEETING 
CRITERIA
% OF SUBJECTS 
WHO MEET 
CRITERIA WITH 
SYMPTOMS 
ABOVE -1
OVERLAP 
COEFFICIENT 
FOR SUBJECTS 
WHO DO AND 
DO NOT MEET 
CRITERIA
MEAN THETA OF 
SUBJECTS WHO 
MEET CRITERIA
SD THETA OF 
SUBJECTS WHO 
MEET CRITERIA
MEAN THETA OF 
SUBJECTS WHO 
DO NOT MEET 
CRITERIA
SD THETA OF 
SUBJECTS WHO 
DO NOT MEET 
CRITERIA
Relief:  
all items ≤2 
0.23 0.08 0.19 0.27 -1.71 0.78 0.15 0.91
Relief:  
5 of 8 items ≤2 
0.51 0.31 0.55 0.32 -1.03 0.72 0.46 0.79
Relief: 
all items ≤3 
0.69 0.37 0.66 0.40 -0.84 0.75 0.50 0.84
Remission 
criteria 
- 0.47 0.66 0.44 -0.80 0.77 0.47 0.86
NOTE: When setting the Relief and Remission criteria at the same threshold (≤3), the subjects identified by both measures had an overlap value of kappa=0.69. The Relief criteria had a 
less ill group than the Remitted group, with less overlap between subjects who did and did not meet criteria.
SD: standard deviation
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analytic and IRT, to discern how well the PANSS 
total scores reflect global symptom severity 
and to what degree meeting the Remission 
criteria identifies individuals who have low 
levels of symptom severity. To address the 
first question, the bifactor models shows that 
88 percent of total symptom score variation 
(ωH coefficient) can be attributed to variation 
in general symptom severity, and only eight 
percent reflected secondary domain factors; 
thus, there is four-percent error variance. 
We can conclude from these values that the 
30-item PANSS is highly reliable and that 
total scores predominantly reflect a general 
latent factor that we termed symptom severity. 
The results suggest that interpretation of 
PANSS scores is not overly complicated or 
compromised by multidimensionality. 
On the other hand, not all PANNS items 
are “good” or “pure” indicators of general 
symptom severity. In fact, there was large 
variation with some items being relatively 
better measures of the general factor than of 
specific domain factors. This fact needs to be 
considered in any future short-form versions 
of PANSS. Ideally, in short form creation, 
items that have high discrimination on the 
general factor, are “univocal” measures of 
the general factor (i.e., with high ECVI), and 
are balanced across the content domains 
(e.g., selecting two items from each domain) 
should be selected. The rationale behind this 
scale construction strategy and how it yields 
the most interpretable scores is beyond the 
present scope, but Stuckey et al16 and Edelen et 
al36 provide lengthy discussions and examples.
Our analysis of the eight-item Remission 
set revealed two important findings. First, 
individuals who were judged Remitted based 
on scoring 3 or below on the remission set, 
scored about 0.8 SD lower in the general 
latent trait θ than non-remitted patients, 
with 43.5 percent overlap between subjects 
who were and were not remitted. However, 
being judged as remitted using these criteria 
is not associated with symptom relief, where 
“relief” is defined by low levels of the latent 
trait reflecting general symptom severity (i.e., 
trait levels less than θ= -1 corresponding to 
average PANSS item scores between 1 and 
2). Post-treatment, 534 individuals (or about 
15% of the whole sample) scored below θ= 
-1 in symptom severity, but 1,351 subjects 
satisfied Remission criteria (37%). Second, our 
analysis of the test information curves for item 
subsets revealed that the Remission set is not 
ideal in terms of discriminating individuals 
along the symptom severity dimension as 
defined by the bifactor IRT model. In fact, 
all tested alternative subsets, especially the 
most discriminating items, outperformed the 
Remission set in the amount of information 
measured (Figure 6). The discrimination items 
were most valuable for testing along the entire 
symptom range (including high severity), 
while the Relief set items were strongest 
for testing in the low-symptom range. One 
advantage of IRT models is that scores are 
derivable based on any subset of items, and 
the metric of the latent variable is easily 
related to the metric of raw scores. Embretson 
et al17 provides further discussion on this topic.
FIGURE 7. The “best” item subset depends on the illness level of the patient being assessed. The items providing the most 
information over the entire latent trait range are those with the largest discrimination parameters, which differ slightly 
from items providing the most information in the Symptom Relief range of θ =(-4,-1). Item scores ≤2 would be associated 
with trait levels below the mean range. Items marked with a * were part of the original remission subset. ECVI (explained 
common variance per item), Discrimination, and Information are rescaled between 0-1 for comparison purposes.
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The frequency (37%) with which the 
Remission criteria are met after treatment 
might be due to multiple sources: a large 
placebo response could have driven down 
some item scores artificially, and these 
short-term gains could disappear within the 
six-month Remission timeframe. The symptom 
changes could be due to score-deflation 
by raters (i.e., given that the expert panel 
identified symptoms that should identify 
overall improvement, it is possible that raters 
anticipated changes in these symptoms even 
more so than other symptoms that were 
not identified by the Remission subgroup, 
suggesting an affirmation bias). Finally, the 
Remission subgroup constructed these criteria 
based on relapse prevention trials, suggesting 
that these studies might be comparing 
different trial populations. 
As shown in Figure 7, the best items to 
be used for assessment ultimately depend 
on the symptom severity level, as different 
items have different utility depending on the 
illness level of the patient. The items with 
the most total information for the entire 
symptom range were those with the largest 
discrimination parameters: Suspiciousness 
Persecution, Excitement, Delusions, Tension, 
Unusual Thought Content, Preoccupation, 
Hostility, and Conceptual Disorganization. 
Unusual Thought Content, Conceptual 
Disorganization, and Delusions were both part 
of the original Remission criteria. The items 
providing the most information for patients 
within the Relief range were calculated using 
the item characteristic curves. These items 
were Delusions, Preoccupation, Suspiciousness 
Persecution, Unusual Thought Content, 
Conceptual Disorganization, Stereotyped 
Thinking, Active Social Avoidance, and Lack of 
Judgment and Insight. Three of these items, 
Delusions, Unusual Thought Content, and 
Conceptual Organization, were contained in 
the original Remission criteria. Lower scores 
on these items (≤2) were strongly associated 
with having a low latent trait θ or attaining 
overall “Symptom Relief.” 
Limitations. There are several limitations 
to our models. First, we treated active and 
placebo interventions identically, although, 
previously, changes had been seen between 
these interventions with IRT models.9 Second, 
patients with reduced symptom severity post-
treatment are not necessarily those who are 
the greatest treatment responders. Third, our 
models and the Relief criteria proposed here 
are specific to those enrolled in a drug trial; 
this might be different than those patients 
seen clinically and those for whom the original 
Remission criteria were established. These 
analyses do not suggest that the Remission 
criteria do not demarcate those with “an 
improvement in core signs and symptoms 
to the extent that any remaining symptoms 
are of such low intensity that they no longer 
interfere significantly with behavior and 
are below the threshold typically utilized in 
justifying an initial diagnosis of schizophrenia” 
as originally intended. The core signs were 
clinically determined for Remission based 
on their relevance to the disorder and their 
impact on patients; the IRT analyses is blind 
to the qualitative impact of symptoms on 
patients and their life outcomes.
Finally, there are also several technical 
concerns that we need to raise, but do not 
have space to fully discuss. First, we needed to 
run the model for a large number of iterations 
in order to meet the convergence criterion 
in mirt, possibly the sign of an unstable 
model. Second, in the bifactor model, the 
Delusions item tended toward a Heywood 
case—very high discrimination—that might 
be affecting other item parameter estimates. 
Third, the results of the factor analysis (limited 
information estimation) did not always align 
perfectly with the result of the IRT analysis 
(full information estimation). Although we did 
not expect perfect alignment, interpretation 
of item quality differed somewhat between 
solutions, which is potentially another sign of 
instability. Finally, we note again that some 
items had cross-loadings in violation of the 
bifactor model, and the overall fit was modest. 
CONCLUSION
The Remission criteria were drafted based 
on clinical expertise and grounded in the 
Diagnostic and Statistical Manual of Mental 
Disorders (DSM), Fourth Edition. Our results 
suggest that the subjects attaining “Symptom 
Relief” measured using the entire PANSS 
scale are not necessarily Remitted, and those 
subjects who attain Remission frequently have 
latent trait scores that suggest moderate-to-
severe overall symptom levels. More generally, 
this disparity between Remission and the 
latent illness level suggests that the PANSS 
differentially assesses patients compared to an 
expert clinician. The term “Symptom Relief” 
is presented here not just as a description of 
the symptom range we are profiling, but also 
to delineate these analyses and these results 
from Remission. The differences between the 
Relief and Remission subsets do not suggest 
that the Relief subset replaces, refutes, or 
contradicts the original Remission criteria, 
because the Relief items are selected to answer 
a different question than the Remission 
objectives; the Relief criteria provide a method 
of identifying patients with low general illness 
severity after the conclusion of a trial, when 
measured using the entire PANSS.
The original Remission criteria were linked 
to what was considered “active illness” in 
the DSM, and were considered definitional 
for schizophrenia and the DSM subtype of 
“schizophrenia in remission.” The findings 
reported here suggest that A) the PANSS 
has a strong general factor reflecting overall 
severity and once this is accounted for there is 
little additional variation in symptoms and B) 
satisfying the proposed criteria for Remission 
is not necessarily associated with low levels 
of general symptom severity. Together these 
findings call into question whether rules 
established to determine satisfaction of 
the diagnostic criteria (specifically the “A” 
criteria of the DSM) are truly the best way to 
characterize whether individuals are still in an 
“active illness” or have recovered well from an 
episode illness. While conceptually appealing, 
there might be value in basing definitions of 
“remission” or “relief” on our best estimates 
of general symptom severity. In constructing 
our criteria for symptom “relief” here, we used 
a direct measure of the general factor (θ≤1) 
based on IRT that identifies individuals who, 
on average, have symptom severity in the 
“absent” to “minimal” range. This approach 
more clearly identifies patients with lower 
severity of symptoms; it remains an empirical 
question whether application of similar criteria 
might be more useful clinically, or in clinical 
trials.
Here, the items with the greatest 
discrimination parameters over the entire 
illness range overlap considerably, but not 
perfectly, with the Relief criteria symptoms. 
This suggests that the utility of any subset 
of PANSS items ultimately depends on the 
population being evaluated. It is likely that the 
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symptoms demarcating Relief post-treatment 
might differ during a different study phase or 
in an unmedicated patient group. Because of 
this, comparison of relative scores using IRT 
methods might permit better identification of 
the “moderately well” patients. 
In conclusion, a reduced symptom burden is 
neither necessary nor sufficient for Remission 
following the AWG/SWG criteria. Subjects with 
symptom Relief post-treatment are not the 
same as those who meet Remission criteria, 
and those who did meet Remission criteria 
frequently overlapped in symptom severity 
with those who were not considered Remitted. 
This does not suggest that the Remission 
criteria do not successfully identify a subset 
of patients for whom “the disease burden was 
substantially lessened” as originally intended; 
the construction of these criteria based on 
the diagnostic criteria rather than empirical 
analyses might capture elements of the 
diagnostic system that are clinically relevant 
and affect aspects of patient’s well-being that 
are not as well addressed by general severity 
of symptoms. The discrepancies between 
these two methods—with Remission 
criteria focused on DSM-defined diagnostic 
classification and with Relief criteria focused 
on the general severity of symptoms as 
measured on the PANSS—point out the need 
for future empirical research to determine the 
advantages of each strategy.
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